Wong-Staal, 1995 - Google Patents
Ribozyme gene therapy for HIV infection Intracellular immunization of lymphocytes and CD34+ cells with an anti-HIV-1 ribozyme geneWong-Staal, 1995
- Document ID
- 9444289608196677835
- Author
- Wong-Staal F
- Publication year
- Publication venue
- Advanced drug delivery reviews
External Links
Snippet
The ultimate goal of gene therapy for HIV infection is to repopulate the immune system with genetically altered cells that would resist infection. We previously reported that a hairpin ribozyme that cleaves HIV-1 RNA in U5 suppressed the replication of diverse strains of HIV …
- 210000004027 cells 0 title abstract description 57
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse Transcribing RNA Viruses
- C12N2740/00011—Reverse Transcribing RNA Viruses
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
- C12N15/1132—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses against retroviridae, e.g. HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/21—Retroviridae, e.g. equine infectious anemia virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6410257B1 (en) | Methods to assay gene function with viral vectors | |
| Strayer et al. | Current status of gene therapy strategies to treat HIV/AIDS | |
| US5670361A (en) | HIV-specific ribozymes | |
| Gervaix et al. | Multigene antiviral vectors inhibit diverse human immunodeficiency virus type 1 clades | |
| JP4384146B2 (en) | Conditionally replicating viral vectors and uses thereof | |
| WO2018006880A1 (en) | Co-expression of recombinant immune-checkpoint receptor and immune-checkpoint inhibitor and application | |
| Wang et al. | Preclinical characterization of an anti-tat ribozyme for therapeutic application | |
| Bai et al. | Multivalent anti-CCR5 ribozymes for stem cell-based HIV type 1 gene therapy | |
| Fanning et al. | Gene therapy for HIV/AIDS: the potential for a new therapeutic regimen | |
| US5885806A (en) | Methods to prepare conditionally replicating viral vectors | |
| US20040132161A1 (en) | Methods and compositions for increasing CD4lymphocyte immune responsiveness | |
| Wong-Staal | Ribozyme gene therapy for HIV infection Intracellular immunization of lymphocytes and CD34+ cells with an anti-HIV-1 ribozyme gene | |
| US20050124645A1 (en) | Methods and compositions for increasing CD4lymphocyte immune responsiveness | |
| US6303334B1 (en) | Nucleic acid encoding a transdominant negative retroviral integrase | |
| Tewari et al. | Inhibition of HIV‐1 replication in primary human T cells transduced with an intracellular anti‐HIV‐1 p17 antibody gene | |
| US20050214258A1 (en) | Vectors for delivering viral and oncogenic inhibitors | |
| WO1998003669A9 (en) | Vectors for inhibiting hiv and tumor growth | |
| Nabel | Gene therapy approaches to AIDS | |
| Wong-Staal | Gene therapy for HIV infection | |
| Gervaix et al. | Gene Therapy for Human Immunodeficiency Virus Infection Using Stem Cell Transplantation | |
| Fanning et al. | Anti-HIV ribozymes in the inhibition of HIV | |
| MEHROTRA et al. | USE OF GENE THERAPY TO CURE AIDS | |
| Firth | HIV AND GENE THERAPY: AReview OF EMERGING TECHNICAL ISSUES CONTRIBUTING TO THE SUCCESS OF CLINICAL APPLICATIONS | |
| Friedman | HIV-1 Latency as a Consequence of Chromatin Regulation | |
| Giraldo et al. | Development of Ribozyme Gene Therapy for |